Clinical Trial Results:
An exploratory, double blind, randomized, placebo-controlled, prallel group, multicenter study, for the assessment of the efficacy, safety and tolerability of ucb34714 50mg oral capsules in b.i.d. administration at the dose of 200mg/day and 400mg/day, in subjects (at least 18 years old) suffering from post-herpetic neuralgia (PHN).
Summary
|
|
EudraCT number |
2004-000975-32 |
Trial protocol |
ES CZ SK |
Global completion date |
05 Jan 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
22 Dec 2016
|
First version publication date |
22 Dec 2016
|
Other versions |
|
Summary report(s) |
Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.